Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.32 Billion USD | 12.01% |
| 2022 | 1.18 Billion USD | 3.85% |
| 2021 | 1.13 Billion USD | 80.4% |
| 2020 | 631.81 Million USD | 22.18% |
| 2019 | 517.11 Million USD | 22.05% |
| 2018 | 423.67 Million USD | 53.54% |
| 2017 | 275.94 Million USD | 556.84% |
| 2016 | 42.01 Million USD | 27.98% |
| 2015 | 32.82 Million USD | 7.16% |
| 2014 | 30.63 Million USD | 2.5% |
| 2013 | 29.88 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.5 Billion USD | 13.71% |
| 2024 Q2 | 1.5 Billion USD | 0.0% |
| 2023 Q1 | 1.29 Billion USD | 9.68% |
| 2023 Q3 | 1.34 Billion USD | 3.44% |
| 2023 Q2 | 1.29 Billion USD | 0.0% |
| 2023 FY | 1.32 Billion USD | 12.01% |
| 2023 Q4 | 1.32 Billion USD | -1.27% |
| 2022 Q4 | 1.18 Billion USD | 0.0% |
| 2022 Q3 | 1.18 Billion USD | -5.75% |
| 2022 Q2 | 1.25 Billion USD | 0.0% |
| 2022 Q1 | 1.25 Billion USD | 10.19% |
| 2022 FY | 1.18 Billion USD | 3.85% |
| 2021 Q3 | 846.17 Million USD | 16.12% |
| 2021 Q4 | 1.13 Billion USD | 34.7% |
| 2021 Q2 | 728.71 Million USD | 0.0% |
| 2021 Q1 | 728.71 Million USD | 15.34% |
| 2021 FY | 1.13 Billion USD | 80.4% |
| 2020 Q3 | 631.81 Million USD | 13.97% |
| 2020 FY | 631.81 Million USD | 22.18% |
| 2020 Q1 | 554.35 Million USD | 7.2% |
| 2020 Q2 | 554.35 Million USD | 0.0% |
| 2020 Q4 | 631.81 Million USD | 0.0% |
| 2019 Q4 | 517.11 Million USD | 0.0% |
| 2019 Q3 | 517.11 Million USD | 22.26% |
| 2019 Q2 | 422.95 Million USD | 0.0% |
| 2019 Q1 | 422.95 Million USD | -0.17% |
| 2019 FY | 517.11 Million USD | 22.05% |
| 2018 Q3 | 153.51 Million USD | -60.96% |
| 2018 Q1 | 128.54 Million USD | -53.42% |
| 2018 Q2 | 393.22 Million USD | 205.91% |
| 2018 Q4 | 423.67 Million USD | 175.98% |
| 2018 FY | 423.67 Million USD | 53.54% |
| 2017 Q3 | 272.71 Million USD | 555.57% |
| 2017 FY | 275.94 Million USD | 556.84% |
| 2017 Q4 | 275.94 Million USD | 1.18% |
| 2017 Q2 | 41.6 Million USD | 7.08% |
| 2017 Q1 | 38.84 Million USD | -7.53% |
| 2016 Q3 | 39.21 Million USD | 3.89% |
| 2016 Q4 | 42.01 Million USD | 7.13% |
| 2016 FY | 42.01 Million USD | 27.98% |
| 2016 Q2 | 37.74 Million USD | 7.54% |
| 2016 Q1 | 35.09 Million USD | 6.92% |
| 2015 Q3 | 30.89 Million USD | 30.14% |
| 2015 Q1 | 23.73 Million USD | -18.67% |
| 2015 Q4 | 32.82 Million USD | 6.25% |
| 2015 FY | 32.82 Million USD | 7.16% |
| 2015 Q2 | 23.73 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 30.63 Million USD | 2.5% |
| 2014 Q4 | 29.18 Million USD | 0.0% |
| 2014 Q3 | 29.18 Million USD | 0.0% |
| 2013 FY | 29.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4833028.477% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -13906.795% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -1729.521% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -163831.994% |
| Rebus Holdings, Inc. | 5.24 Million USD | -25193.249% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -2146.706% |
| Qrons Inc. | 1.48 Million USD | -88961.635% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -108027.392% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -1669.717% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2966322.353% |
| Skye Bioscience, Inc. | 14.07 Million USD | -9321.906% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -2387.332% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -13737.081% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -314409.672% |
| SQZ Biotechnologies Company | 50.03 Million USD | -2549.678% |
| Intellipharmaceutics International Inc. | 12 Million USD | -10940.868% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -34325.504% |
| Mesoblast Limited | 188.44 Million USD | -603.587% |
| Marizyme, Inc. | 26.67 Million USD | -4870.335% |
| Genus plc | 485 Million USD | -173.376% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -22593.105% |
| Pharming Group N.V. | 244.07 Million USD | -443.228% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -65859.522% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -52590.752% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -34791.372% |
| ContraFect Corporation | 32.53 Million USD | -3975.719% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -66819.032% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -34539.343% |
| IMV Inc. | 37.93 Million USD | -3395.319% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -11157.006% |
| MultiCell Technologies, Inc. | 1617.67 USD | -81961742.341% |
| ONE Bio Corp. | 27.49 Million USD | -4722.088% |
| Accustem Sciences Inc. | 1.07 Million USD | -122752.504% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -1612.637% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -62586.945% |
| Q BioMed Inc. | 8.13 Million USD | -16202.497% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -1498.688% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -25664.926% |
| Biomind Labs Inc. | 1.49 Million USD | -88373.343% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -1016.785% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -14563.168% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -7104.49% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -92368.666% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -932988.522% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -659157.411% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -22975.417% |
| GB Sciences, Inc. | 5.41 Million USD | -24373.617% |
| Alpha Cognition Inc. | 7.16 Million USD | -18405.429% |
| HST Global, Inc. | 593.59 Thousand USD | -223263.843% |
| CSL Limited | 18.62 Billion USD | 92.88% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -105195.386% |
| Halberd Corporation | 728.71 Thousand USD | -181845.597% |
| Enzolytics Inc. | 365.26 Million USD | -262.985% |
| Agentix Corp. | 2.51 Million USD | -52711.914% |
| Resverlogix Corp. | 67.39 Million USD | -1867.286% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -157980.547% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -197.982% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -77255.434% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -5257.919% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -11038.88% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -36074.974% |
| AVAX Technologies, Inc. | 3.99 Million USD | -33098.718% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4809186.282% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -555462.503% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -35405.182% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -194642.351% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -48795.563% |
| Kadimastem Ltd | 3.5 Million USD | -37729.456% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1980912.917% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -2537.817% |
| BioStem Technologies, Inc. | 15.9 Million USD | -8236.372% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -285218.483% |
| LadRx Corporation | 2.2 Million USD | -60152.455% |
| Cell Source, Inc. | 15.8 Million USD | -8288.031% |
| Regen BioPharma, Inc. | 5.45 Million USD | -24193.98% |
| Regen BioPharma, Inc. | 5.45 Million USD | -24193.98% |
| NovAccess Global Inc. | 7.86 Million USD | -16767.031% |
| Affymax, Inc. | 8.87 Million USD | -14846.141% |
| Itoco Inc. | 1.65 Million USD | -80102.724% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -64527.352% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -21818.865% |
| Mobile Lads Corp. | 1.31 Million USD | -100842.152% |
| CytoDyn Inc. | 127.89 Million USD | -936.696% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3171918.792% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -84545.787% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -11903.961% |
| SYBLEU INC | 681.41 Thousand USD | -194476.877% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -21628.823% |
| International Stem Cell Corporation | 5.27 Million USD | -25025.491% |
| Bioxytran, Inc. | 3.24 Million USD | -40702.343% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -211765.303% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -28616.401% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -3134.15% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -5854.961% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -65362.657% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -24103.58% |
| Neutra Corp. | 973.52 Thousand USD | -136092.362% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -4469.609% |
| PureTech Health plc | 125.58 Million USD | -955.774% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -35189.54% |
| IXICO plc | 1.9 Million USD | -69672.021% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -6358.532% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1183.218% |
| CSL Limited | 18.62 Billion USD | 92.88% |
| Cellectis S.A. | 249.36 Million USD | -431.69% |